Single-molecule analysis reveals widespread structural variation in multiple myeloma

Significance In the last several years, we have seen significant progress toward personalized cancer genomics and therapy. Although we routinely discern and understand genomic variation at single base pair and chromosomal levels, comprehensive analysis of genome variation, particularly structural variation, remains a challenge. We present an integrated approach using optical mapping—a single-molecule, whole-genome analysis system—and DNA sequencing to comprehensively identify genomic structural variation in sequential samples from a multiple myeloma patient. Through our analysis, we have identified widespread structural variation and an increase in mutational burden with tumor progression. Our findings highlight the need to routinely incorporate structural variation analysis at many length scales to understand cancer genomes more comprehensively. Multiple myeloma (MM), a malignancy of plasma cells, is characterized by widespread genomic heterogeneity and, consequently, differences in disease progression and drug response. Although recent large-scale sequencing studies have greatly improved our understanding of MM genomes, our knowledge about genomic structural variation in MM is attenuated due to the limitations of commonly used sequencing approaches. In this study, we present the application of optical mapping, a single-molecule, whole-genome analysis system, to discover new structural variants in a primary MM genome. Through our analysis, we have identified and characterized widespread structural variation in this tumor genome. Additionally, we describe our efforts toward comprehensive characterization of genome structure and variation by integrating our findings from optical mapping with those from DNA sequencing-based genomic analysis. Finally, by studying this MM genome at two time points during tumor progression, we have demonstrated an increase in mutational burden with tumor progression at all length scales of variation.

[1]  B. Barlogie,et al.  The growth fraction of human myeloma cells. , 1981, Blood.

[2]  Bradley P. Coe,et al.  Genome structural variation discovery and genotyping , 2011, Nature Reviews Genetics.

[3]  G. Parmigiani,et al.  Heterogeneity of genomic evolution and mutational profiles in multiple myeloma , 2014, Nature Communications.

[4]  S. Miyamoto,et al.  Perillyl alcohol inhibits a calcium-dependent constitutive nuclear factor-kappaB pathway. , 2005, Cancer research.

[5]  Thomas W. Mühleisen,et al.  Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk , 2011, Nature Genetics.

[6]  Tatiana Popova,et al.  Supplementary Methods , 2012, Acta Neuropsychiatrica.

[7]  M. Hurles,et al.  Copy number variation in human health, disease, and evolution. , 2009, Annual review of genomics and human genetics.

[8]  P. L. Bergsagel,et al.  Molecular pathogenesis of multiple myeloma and its premalignant precursor. , 2012, The Journal of clinical investigation.

[9]  A. Shilatifard,et al.  The super elongation complex (SEC) and MLL in development and disease. , 2011, Genes & development.

[10]  S. Rajkumar,et al.  The current status of minimal residual disease assessment in myeloma , 2014, Leukemia.

[11]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.

[12]  A. McKenna,et al.  Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. , 2014, Cancer cell.

[13]  Thomas W. Mühleisen,et al.  Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk , 2013, Nature Genetics.

[14]  G. Morgan,et al.  A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. , 2010, Blood.

[15]  O. Abdel-Wahab,et al.  The role of mutations in epigenetic regulators in myeloid malignancies , 2012, Nature Reviews Cancer.

[16]  David C. Schwartz,et al.  High-resolution human genome structure by single-molecule analysis , 2010, Proceedings of the National Academy of Sciences.

[17]  M. Gerstein,et al.  CNVnator: an approach to discover, genotype, and characterize typical and atypical CNVs from family and population genome sequencing. , 2011, Genome research.

[18]  Philip M. Kim,et al.  Paired-End Mapping Reveals Extensive Structural Variation in the Human Genome , 2007, Science.

[19]  Deepayan Sarkar,et al.  Discovery of structural alterations in solid tumor oligodendroglioma by single molecule analysis , 2013, BMC Genomics.

[20]  K. Vanderkerken,et al.  The role of the insulin-like growth factor 1 receptor axis in multiple myeloma , 2009, Archives of physiology and biochemistry.

[21]  R. Wilson,et al.  BreakDancer: An algorithm for high resolution mapping of genomic structural variation , 2009, Nature Methods.

[22]  G. Morgan,et al.  Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. , 2013, Blood.

[23]  Kai Ye,et al.  Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads , 2009, Bioinform..

[24]  C Bifulco,et al.  The A-Myb transcription factor is a marker of centroblasts in vivo. , 1998, Journal of immunology.

[25]  David C. Schwartz,et al.  An algorithm for assembly of ordered restriction maps from single DNA molecules , 2006, Proceedings of the National Academy of Sciences.

[26]  G. Morgan,et al.  Deletions of CDKN2C in Multiple Myeloma: Biological and Clinical Implications , 2008, Clinical Cancer Research.

[27]  E. Terpos,et al.  No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib. , 2006, Leukemia research.

[28]  Asta Försti,et al.  The CCND1 870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma , 2013, Nature Genetics.

[29]  D. Dingli,et al.  Improved survival in multiple myeloma and the impact of novel therapies. , 2008, Blood.

[30]  J. Carpten,et al.  Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. , 2012, Blood.

[31]  David C. Schwartz,et al.  Statistical Significance of Optical Map Alignments , 2012, J. Comput. Biol..

[32]  Juan J de Pablo,et al.  A microfluidic system for large DNA molecule arrays. , 2004, Analytical chemistry.

[33]  David C. Schwartz,et al.  A large, complex structural polymorphism at 16p12.1 underlies microdeletion disease risk , 2010, Nature Genetics.

[34]  KyungMann Kim,et al.  Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells , 2010, Molecular Cancer.

[35]  Y. Pekarsky,et al.  Tcl1 as a model for lymphomagenesis. , 2004, Hematology/oncology clinics of North America.

[36]  S. Rajkumar,et al.  Multiple myeloma: 2012 update on diagnosis, risk‐stratification, and management , 2012, American journal of hematology.

[37]  David C. Schwartz,et al.  Refinement of optical map assemblies , 2006, Bioinform..

[38]  S. Lonial,et al.  PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. , 2007, Future oncology.

[39]  Yi Yang,et al.  Alignment of Optical Maps , 2005, RECOMB.

[40]  Trevor J Pugh,et al.  Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.